Preoperative CA 19-9 and the Pattern and Timing of Recurrence After Pancreatoduodenectomy (Whipple Operation) for Pancreatic Cancer
A legfontosabb adatok
- Ki végzi
- Minia University
- Hol
- Egyiptom2 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 180 fő, tervezett
- Kezdés
- 2026. dec. 1.
- Várható befejezés
- 2027. ápr. 30.
- A vizsgálat típusa
- Megfigyeléses, 2 csoport
- A vizsgált kezelések
- Pancreatoduodenectomy
- Index preoperative serum CA 19-9
- A regiszteradat frissítve
- 2026. november 18.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 14 feltétel megnézéseKevesebb
Ki vehet részt
- Age 18 years or older at operation
- Pancreatoduodenectomy (classical Whipple or pylorus-preserving; open or minimally invasive) with curative intent between 1 January 2017 and 31 December 2024 at the Liver and GIT Hospital, Minia University
- Histologically confirmed pancreatic ductal adenocarcinoma, including accepted morphological variants, of the pancreatic head or uncinate process
- Macroscopically complete resection (R0 or R1; R1 defined as tumour within 1 mm of a resection margin)
- Index preoperative serum CA 19-9 available: measured within 30 days before operation with a total bilirubin ≤2 mg/dL drawn within 72 hours of the CA 19-9 sample (the post-drainage value where preoperative biliary drainage was performed)
- Follow-up of at least 6 months, or documented recurrence or death at any earlier point
Ki nem vehet részt
- Neoadjuvant chemotherapy or chemoradiotherapy (such patients are described in a supplementary table only and never pooled with the principal cohort)
- R2 resection, aborted resection, or M1 disease at operation, including histologically confirmed para-aortic (station 16) nodal metastasis at resection
- Synchronous second malignancy under treatment, or prior malignancy treated within 5 years, other than adequately treated non-melanoma skin cancer or in-situ cervical carcinoma
- No preoperative CA 19-9 within 30 days, or none obtainable at a total bilirubin ≤2 mg/dL (these patients form the secondary cohort, used only in sensitivity analysis S2)
- Histology other than pancreatic ductal adenocarcinoma: ampullary carcinoma, distal cholangiocarcinoma, duodenal carcinoma, neuroendocrine neoplasm, acinar cell carcinoma, solid pseudopapillary neoplasm, non-invasive intraductal papillary mucinous neoplasm, or metastasis from another primary
- Body or tail tumour requiring distal pancreatectomy, or total pancreatectomy performed
- Death within 90 days of operation without documented recurrence (reported separately as postoperative mortality)
- Records irretrievable, or too incomplete to determine the exposure or the primary outcome
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Surgery to remove the head of the pancreas (pancreatoduodenectomy, also called the Whipple operation), usually followed by chemotherapy, is the only treatment that offers long-term survival for cancer in the head of the pancreas (pancreatic ductal adenocarcinoma). Even so, the cancer comes back (recurs) in most patients. Where it comes back first (around the operation site, in the liver, in the lining of the abdomen, in the lungs or elsewhere) and how soon it comes back both affect survival, the choice of further treatment and how patients should be followed up.
A teljes eredeti leírásKevesebb
CA 19-9 is a blood test measured routinely before this operation. A high level is known to be linked with shorter survival, but whether it also predicts where and when the cancer will recur is uncertain and, to the investigator's knowledge, has not been studied in patients treated in Egypt. Jaundice, which is common in these patients, can raise CA 19-9 falsely, so this study uses only CA 19-9 values measured when the blood bilirubin level was close to normal (2 mg/dL or less).
This is a retrospective study of existing medical records. It includes adults who had a Whipple operation for this cancer at the Hepatopancreatobiliary and Surgical Oncology Unit, Liver and GIT Hospital, Minia University, Egypt, between January 2017 and December 2024, with follow-up information from Minia Oncology Centre. No patient will receive any test or treatment for the study, and no care will be changed. Patients will be compared according to their preoperative CA 19-9 level (37 U/mL or less versus more than 37 U/mL).
The two main questions are whether the preoperative CA 19-9 level is linked to (1) the site of the first recurrence and (2) the time from surgery to recurrence. A recurrence will count only when confirmed by scans or biopsy, never by a rising CA 19-9 alone, and it will be classified by independent doctors who do not know the patients' CA 19-9 results. Other questions include recurrence within 6 and 12 months of surgery, survival, and whether CA 19-9 adds useful information to the routine findings available before surgery.
The investigator expects that patients with a high CA 19-9 will more often recur first in the liver or the lining of the abdomen and will recur sooner, whereas patients with a normal level will recur later and more often only near the operation site. The findings may help tailor follow-up after surgery, identify patients who might benefit from chemotherapy before surgery, and identify patients whose cancer is likely to come back only at the operation site, who might be considered for further local treatment.
A vizsgálat 2 csoportja
- Normal preoperative CA 19-9 (≤37 U/mL)
Adults who underwent curative-intent pancreatoduodenectomy for pancreatic ductal adenocarcinoma of the head or uncinate process between 1 January 2017 and 31 December 2024 whose index preoperative serum CA 19-9 was ≤37 U/mL. The index value is the last CA 19-9 within 30 days before surgery drawn within 72 hours of a total bilirubin ≤2 mg/dL and, after preoperative biliary drainage, the post-drainage value. Includes presumed Lewis-negative non-secretors (\<2 U/mL) and normal levels (2-37 U/mL), also reported as separate ordinal strata; non-secretors are removed from this group in sensitivity analysis S1. Reference group for the primary contrast. Surgery and CA 19-9 testing were delivered as routine care; nothing is assigned or changed by the study.
Kezelés: Pancreatoduodenectomy és Index preoperative serum CA 19-9
- Elevated preoperative CA 19-9 (>37 U/mL)
Adults who underwent curative-intent pancreatoduodenectomy for pancreatic ductal adenocarcinoma of the head or uncinate process between 1 January 2017 and 31 December 2024 whose index preoperative serum CA 19-9 (same bilirubin-qualified definition) was \>37 U/mL. Subdivided for descriptive and trend analyses into moderately elevated (\>37-200 U/mL) and markedly elevated (\>200 U/mL) strata. Exposed group for the primary contrast. Surgery and CA 19-9 testing were delivered as routine care; nothing is assigned or changed by the study.
Kezelés: Pancreatoduodenectomy és Index preoperative serum CA 19-9
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Correlation of Preoperative Serum CA 19-9 With the Pattern and Timing of Recurrence After Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Retrospective Cohort Study
- A regiszteradat frissítve
- 2026. november 18.